Clinical trial · Observational
The Effect of TRA-8 on Ovarian Cancer Tissue
Death Receptor-Mediated Apoptosis and Therapy Strategies in Ovarian Cancer
NCT00711932CI-TRIAL-00012048completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The goal of this study is to determine the apoptosis-inducing efficacy of TRA-8 in patient ovarian cancer tissues using a tissue slice technology. In addition, we want to evaluate the expression of apoptosis regulatory proteins using multiplex proteomic technology and its correlation with TRA-8-induced cytotoxicity in patient ovarian cancer tissues.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Ovarian Cancer | Malignant Ovarian Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (2)
- measure
- Presence of TRA-8 apoptosis
- timeFrame
- At the time of surgery
- description
- Apoptosis properties of TRA-8 will be analyzed in tissue collected from surgery using tissue slice technology.
- measure
- Presence of apoptosis regulatory proteins
- timeFrame
- At the time of surgery
- description
- The presence of apoptosis regulatory properties will be analyzed in tissue collected from surgery using multiplex proteomic technology.
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 19 Years
Show eligibility criteria text
Inclusion Criteria: * Patients must have suspected ovarian cancer and must be a candidate for surgery. * Patients must have provided a signed consent form. * Patients must have extra tumor at the time of surgery that is appropriate for tumor slicing. * Patients must be at least 19 years of age. * Patients must have histologically confirmed epithelial carcinoma of the ovary or of extra-ovarian origin, any histologic subtype or stage. Exclusion Criteria: * Patients who have received any prior therapy for ovarian cancer.
References
Publications (0)
Data not yet available
No reference posted for this study.